Furthermore, high expression of TNXB is correlated with a higher cancer survival prognosis [70], which showed that the TNXB+ fibroblasts may be associated with NSCLC cancer survival prognosis, further indicating that SMI assisting PD-1 inhibitor may prolong the survival of NSCLC patients by increasing the proportion of TNXB+ fibroblasts. Here, PDCD1 is linked to non-small cell lung carcinoma.